Nuveen LLC Invests $250,000 in Zenas BioPharma, Inc. $ZBIO

Key Points

• Nuveen LLC has acquired a new stake in Zenas BioPharma, buying 31,626 shares valued at approximately $250,000.
• Zenas BioPharma's stock has seen a significant increase of 20.8% recently, with a current trading price of $20.51.
• Analysts have given Zenas BioPharma a consensus rating of "Buy", with a high price target set as much as $36.67.

Nuveen LLC acquired a new stake in shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 31,626 shares of the company's stock, valued at approximately $250,000. Nuveen LLC owned about 0.08% of Zenas BioPharma as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, New York State Common Retirement Fund purchased a new stake in Zenas BioPharma during the first quarter valued at $49,000.

Zenas BioPharma Stock Performance

NASDAQ:ZBIO traded up $0.38 during mid-day trading on Thursday, hitting $20.17. 118,479 shares of the company traded hands, compared to its average volume of 223,124. The company has a fifty day moving average of $15.62. Zenas BioPharma, Inc. has a one year low of $5.83 and a one year high of $26.25. The company has a market cap of $849.36 million and a price-to-earnings ratio of -5.68.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.23).

Analyst Ratings Changes

A number of analysts recently commented on ZBIO shares. Wedbush reiterated an "outperform" rating and set a $35.00 price objective on shares of Zenas BioPharma in a research report on Thursday, May 15th. Wall Street Zen upgraded Zenas BioPharma from a "sell" rating to a "hold" rating in a research report on Friday, September 5th. Finally, HC Wainwright reiterated a "buy" rating and set a $30.00 price objective on shares of Zenas BioPharma in a research report on Friday, May 16th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Zenas BioPharma has a consensus rating of "Buy" and an average target price of $36.67.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.